NCT02575339 - MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2016

Primary Completion Date

June 26, 2018

Study Completion Date

November 24, 2020

Conditions

Hepatocellular CarcinomaLiver CancerHCC

Interventions

DRUG

MLN0128

Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW

DRUG

MLN0128 (RP2D)

"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."

DRUG

Sorafenib

"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"

Trial Locations (6)

Penn State Cancer Institute, Hershey

University of Noth Carolina at Chapel Hill, Chapel Hill

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

University of Wisconsin, Madison

Northwestern University Feinberg School of Medicine, Chicago

University of Illinois Cancer Center, Chicago